13F Holdings
中文EN

WST WEST PHARMACEUTICAL SERVICES INC

Surgical & Medical Instruments & Apparatus · NYSE · SEC CIK 105770 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY12.6%
TTM net income YoY29.9%
TTM EPS YoY32.0%
Revenue 3-yr CAGR5.1%
Net income 3-yr CAGR4.5%

Margins

Gross margin37.6%
Operating margin23.0%
Net margin18.8%
FCF margin13.3%
EBITDA margin28.4%

Returns

ROE21.2%
ROA15.6%
ROIC (approx.)23.0%
Asset turnover0.83x

Leverage & solvency

Liabilities / assets26.9%
Debt / equity0.07x
Current ratio2.82x
Interest coverage96.32x

Cash quality & payout

Operating cash flow / net income1.02x
Accruals ratio-0.4%
Payout ratio9.8%
Capex / revenue5.9%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$3.07B$2.89B$2.95B$2.89B$2.83B
Cost of revenue$1.97B$1.89B$1.82B$1.75B$1.66B
Gross profit$1.10B$998.50M$1.13B$1.14B$1.18B
R&D expense$74.30M$69.10M$68.40M$58.50M$52.80M
SG&A expense$393.60M$338.50M$353.40M$316.90M$362.80M
Operating income$584.90M$569.90M$676.00M$734.00M$752.30M
Interest expense$500,000$3.00M$9.00M$7.90M$8.20M
Pretax income$600.90M$585.50M$698.00M$679.90M$748.90M
Income tax$121.60M$107.50M$122.30M$114.70M$107.20M
Net income$493.70M$492.70M$593.40M$585.90M$661.80M
EBITDA$756.30M$725.30M$813.30M$854.60M$874.60M
EPS (basic)6.836.757.987.878.89
EPS (diluted)6.796.697.887.738.67
Dividends declared per share0.860.820.780.740.70
Weighted avg. shares (diluted)72.70M73.70M75.30M75.80M76.30M
Balance sheet
Cash & equivalents$791.30M$484.60M$853.90M$894.30M$762.60M
Receivables$574.40M$552.50M$512.00M$507.40M$489.00M
Inventory$443.90M$377.00M$434.70M$414.80M$378.40M
Current assets$1.98B$1.54B$1.94B$1.92B$1.74B
PP&E, net$1.73B$1.58B$1.41B$1.16B$1.06B
Goodwill$109.90M$106.00M$108.50M$107.30M$109.90M
Intangibles$7.70M$10.80M$15.10M$18.40M$23.00M
Total assets$4.27B$3.64B$3.83B$3.62B$3.31B
Current liabilities$654.90M$550.40M$671.80M$519.00M$594.10M
Short-term debt$0$0$134.00M$2.20M$44.20M
Long-term debt$202.80M$202.60M$72.80M$206.70M$208.80M
Total debt$202.80M$202.60M$206.80M$208.90M$253.00M
Total liabilities$1.09B$961.10M$948.50M$931.90M$978.40M
Shareholders' equity$3.18B$2.68B$2.88B$2.68B$2.34B
Net debt-$588.50M-$282.00M-$647.10M-$685.40M-$509.60M
Shares outstanding72.00M72.30M73.50M74.10M74.20M
Cash flow statement
Operating cash flow$754.80M$653.40M$776.50M$724.00M$584.00M
Capital expenditure$285.90M$377.00M$362.00M$284.60M$253.40M
Free cash flow$468.90M$276.40M$414.50M$439.40M$330.60M
Investing cash flow-$285.90M-$378.70M-$368.70M-$288.20M-$253.10M
Financing cash flow-$185.10M-$622.60M-$459.60M-$293.60M-$168.10M
Depreciation & amortization$171.40M$155.40M$137.30M$120.60M$122.30M
Stock-based compensation$23.80M$18.70M$23.30M$23.70M$37.50M
Dividends paid$61.20M$59.10M$57.00M$54.10M$51.10M
Share buybacks$134.00M$560.90M$438.30M$202.80M$137.10M

Free plan shows the latest 5 periods; Pro shows all 18 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.